Skip to main content
. 2019 Apr 20;220(5):841–851. doi: 10.1093/infdis/jiz180

Table 2.

Association of Kaposi’s Sarcoma–Associated Herpesvirus Viral Load With 12-Week Mortality

Group KSHV Viral Load Died, No. (%) Survived, No. (%) OR (95% CI) P Valuea
Group 1: Entire patient cohort (n = 675) >100 copies/106 cells 9 (1.3) 24 (3.6) 1.3 (.6–3.0) .455b
≤100 copies/106 cells or nondetectable 137 (20.3) 493 (73.0)
Group 2: Patients with microbiologically proven TB (n = 500) >100 copies/106 cells 3 (0.4) 20 (3.0) 0.5 (.2–1.7) .281b
≤100 copies/106 cells or nondetectable 106 (15.7) 363 (53.8)
Group 3: Patients without proven TB (n = 175) >100 copies/106 cells 6 (0.9) 4 (0.6) 6.3 (1.7–23.7) .008c
≤100 copies/106 cells or nondetectable 31 (4.6) 130 (19.3)
Group 4: Patients without microbiologically confirmed infections (n = 159) >100 copies/106 cells 5 (0.7) 3 (0.4) 7.1 (1.6–31.7) .011c
≤100 copies/106 cells or nondetectable 28 (4.1) 120 (17.8)

Frequency of mortality among patients with elevated KSHV viral load (>100 copies/106 cells) vs those with undetectable KSHV viral load or viral load ≤100 copies/106 cells. Twelve patients of the total cohort were lost to follow-up.

Abbreviations: CI, confidence interval; KSHV, Kaposi’s sarcoma–associated herpesvirus; OR, odds ratio; TB, tuberculosis.

a P value refers to the frequency of elevated KSHV viral load (categorical variable) in patients with confirmed vital status.

bχ2 test for association if expected cell frequencies were >5.

cFisher exact test.